Buscar
Congreso SOLACI

Búsqueda de: dual antiplatelet therapy

Si no está conforme con los resultados, inténtelo de nuevamente.
Acute coronary syndromes

Dual Antiplatelet Therapy in Diabetic Patients with AMI: De-Escalation Strategy

Diabetes Mellitus (DM) is a common comorbidity in patients hospitalized for acute coronary syndrome (ACS) of increasing...
Dr. Andrés Rodríguez -
Ir
Acute coronary syndromes

ESC 2025 | DUAL-ACS: Duration of Dual Antiplatelet Therapy in Acute Coronary Syndromes

The DUAL-ACS trial, a randomized multicenter study, was designed to evaluate whether a strategy of P2Y12 inhibitor...
Dr. Juan Manuel Pérez -
Ir
Acute coronary syndromes

Abbreviated Dual Antiplatelet Therapy with Prasugrel: 4D-ACS

The optimal duration of dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) remains subject to controversy....
Dr. Omar Tupayachi -
Ir
Acute coronary syndromes

EuroPCR 2025 | 4D-ACS Study: One-Month Dual Antiplatelet Therapy Followed by Low-Dose Prasugrel Monotherapy

While dual antiplatelet therapy (DAPT) has long been the standard treatment for managing patients with acute coronary...
Dr. Andrés Rodríguez -
Ir
Antithrombotic Anticoagulants

Is Clopidogrel Monotherapy Safe After a Month of Dual Antiplatelet Therapy in Diabetic Patients?

Currently, many randomized studies have suggested that short-term dual antiplatelet therapy (DAPT) followed by monotherapy reduces bleeding...
solaci -
Ir
Antiplatelet

ESC 2021 | MASTER DAPT: Dual Antiplatelet Therapy After Coronary Angioplasty in Patients at High Bleeding Risk

Courtesy of Dr. José Álvarez. In patients at high bleeding risk with drug-eluting stents, the duration of dual...
solaci -
Ir
Antiplatelet

Very Short Dual Antiplatelet Therapy after Complex PCI

The 1-month outcomes of dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy were comparable to 12-month DAPT...
solaci -
Ir
Antiplatelet

Single or Dual Antiplatelet Therapy in Stroke or Transient Ischemic Attack?

Antiplatelet therapy is key to prevent thrombotic events after a transient ischemic attack (TIA) or ischemic stroke....
solaci -
Ir

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Hybrid Coronary Revascularization versus Conventional Bypass Surgery in Left Main Coronary Artery Disease

Dr. Juan Manuel Pérez - 0
Significant left main coronary artery (LMCA) disease continues to represent a therapeutic challenge, particularly in patients with complex multivessel disease and high SYNTAX scores,...

VECTOR: First Percutaneous Aorto-Coronary Bypass Case, a New Conceptual Approach

Dr. Omar Tupayachi - 0
Coronary obstruction represents one of the most severe complications associated with transcatheter aortic valve implantation, particularly in valve-in-valve scenarios involving surgical bioprostheses, narrow aortic...

Comparison of strategies: NMA of IVUS, OCT, or angiography in complex lesions

Dr. Omar Tupayachi - 0
Percutaneous coronary intervention (PCI) in complex lesions continues to represent a technical challenge in contemporary interventional cardiology. Angiography, although it remains the most widely...

Noticias Institucionales

Technical Training in Hemodynamics and Interventional Cardioangiology | SOLACI–CACI

solaci - 0
The SOLACI–CACI Technical Training in Hemodynamics and Interventional Cardioangiology is an academic program designed for the initial training and professional development of non-physician healthcare...

SOLACI Webinar for Nurses and Technicians | Cardiovascular Risk Factors in Women

solaci - 0
Cardiovascular disease remains the leading cause of death in women. Do we truly understand its risk factors and warning signs? 📢 We invite you to...

SOLACI Session at Miami Valves 2026

solaci - 0
Once again, the Latin American Society of Interventional Cardiology will be present at one of the most important congresses worldwide in the field, with...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad